Ellis J. Neufeld, M.D., Ph.D., has been appointed clinical director, physician-in-chief and executive vice president of St. Jude Children’s Research Hospital.
Neufeld’s appointment will begin in March 2017. In this role, Neufeld will oversee the organization’s academic clinical departments and all clinical operations. The appointment comes as St. Jude launches a focused effort to increase the number of cancer patients treated at its campus and on protocols around the world.
An internationally respected leader in pediatric hematology, Neufeld comes to St. Jude from Boston, where he served on the faculty of Harvard Medical School for the last 26 years. He was most recently associate chief of the Division of Hematology/Oncology at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Neufeld was also medical director at the Boston Hemophilia Center and held the Egan Family Foundation Chair in Transitional Medicine at Harvard Medical School as a professor of pediatrics.
“Dr. Neufeld’s leadership and experience will help steer St. Jude clinical operations as we expand our patient care programs, increase the number of patients treated and work to set the standard for pediatric cancer care delivery,” said James R. Downing, M.D., St. Jude president and chief executive officer.
Neufeld completed his undergraduate work at Wesleyan University in Connecticut, earning his doctoral degrees at Washington University in St. Louis. He then completed specialty training in pediatrics and medical genetics at Boston Children’s Hospital and in pediatric hematology/oncology at Dana-Farber Cancer Institute and Boston Children’s.
He has worked as a physician-scientist in the laboratory and as a clinical researcher in non-malignant hematology with numerous publications in the areas of hemophilia, thalassemia and immune thrombocytopenia.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 50 years ago. St. Jude shares the discoveries it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.